Risk factors for myelosuppression in chronic phase CML patients treated with Imatinib mesylate (STI571).

被引：0
|
作者：
Mauro, MJ
O'Dwyer, ME
Kurilik, G
Blasdel, C
Farnsworth, M
Fong, D
Hsieh, YC
Mori, M
Ford, JM
Druker, BJ
机构：
[1] Oregon Hlth Sci Univ, Leukemia Ctr, Portland, OR 97201 USA
[2] Univ Hong Kong, Clin Trials Ctr, Hong Kong, Hong Kong, Peoples R China
[3] Novartis Pharma, Basel, Switzerland
来源：
BLOOD | 2001年 / 98卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
585
引用
收藏
页码：139A / 139A
页数：1
相关论文
共 50 条
  • [31] Reversal of bone marrow angiogenesis in chronic myeloid leukemia following imatinib mesylate (STI571) therapy
    Kvasnicka, HM
    Thiele, J
    Staib, P
    Schmitt-Graeff, A
    Griesshammer, M
    Klose, J
    Engels, K
    Kriener, S
    BLOOD, 2004, 103 (09) : 3549 - 3551
  • [32] Effects of the tyrosine kinase inhibitor Imatinib mesylate (STI571) on bone marrow features in patients with chronic myelogenous leukemia
    Thiele, J
    Kvasnicka, HM
    Schmitt-Graeff, A
    Kriener, S
    Engels, K
    Staib, P
    Griesshammer, M
    Waller, CF
    Ottmann, OG
    Hansmann, M
    HISTOLOGY AND HISTOPATHOLOGY, 2004, 19 (04) : 1277 - 1288
  • [33] Efficacy of imatinib mesylate (STI571) in chronic neutrophilic leukemia with t(15;19): Case report
    Choi, IK
    Kim, BS
    Lee, KA
    Ryu, S
    Seo, HY
    Sul, H
    Choi, JG
    Sung, HJ
    Park, KH
    Yoon, SY
    Oh, SC
    Seo, JH
    Choi, CW
    Shin, SW
    Yoon, SY
    Cho, YJ
    Kim, YK
    Kim, YH
    Kim, JS
    AMERICAN JOURNAL OF HEMATOLOGY, 2004, 77 (04) : 366 - 369
  • [34] Dose-limiting dermatological toxicity secondary to imatinib mesylate (STI571) in chronic myeloid leukaemia
    D Milojkovic
    K Short
    J R Salisbury
    D Creamer
    A W P du Vivier
    G J Mufti
    Leukemia, 2003, 17 : 1414 - 1416
  • [35] The effect of Gleevec (STI571;imatinib mesylate) in patients with Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML) with secondary chromosomal aberrations.
    Mohamed, AN
    Pemberton, P
    Zonder, JA
    Homisha, S
    Ford, J
    Schiffer, CA
    BLOOD, 2001, 98 (11) : 560A - 560A
  • [36] Apoptotic synergism between histone deacetylase (HDAC) inhibitor and imatinib mesylate (STI571, Glivec®) on chronic myelogenous leukemia (CML) cell lines
    Kim, Byung-Su
    Choi, Yong-Hee
    Kim, Young Jue
    Bae, Eun Kyung
    Ahn, Kwang-Sung
    Park, Seonyang
    Kim, Byoung Kook
    Kim, Yeul Hong
    Yoon, Sung-Soo
    ANNALS OF ONCOLOGY, 2004, 15 : 159 - 159
  • [37] Efficacy of imatinib mesylate (STI571) treatment for a patient with rheumatoid arthritis developing chronic myelogenous leukemia
    Miyachi, K
    Ihara, A
    Hankins, RW
    Murai, R
    Maehiro, S
    Miyashita, H
    CLINICAL RHEUMATOLOGY, 2003, 22 (4-5) : 329 - 332
  • [38] Dose-limiting dermatological toxicity secondary to imatinib mesylate (STI571) in chronic myeloid leukaemia
    Milojkovic, D
    Short, K
    Salisbury, JR
    Creamer, D
    du Vivier, AWP
    Mufti, GJ
    LEUKEMIA, 2003, 17 (07) : 1414 - 1416
  • [39] Results of imatinib mesylate (STI571) therapy in patients (pts) with chronic myelogenous leukemia (CML) in relapse after allogeneic stem cell transplantation (allo SCT).
    Kantarjian, HM
    O'Brien, S
    Cortes, J
    Giralt, S
    Rios, MB
    Shan, J
    Giles, F
    Thomas, D
    Faderl, S
    de Lima, M
    Arlinghaus, RB
    Garcia-Manero, G
    Issa, JP
    Resta, D
    Capdeville, R
    Talpaz, M
    BLOOD, 2001, 98 (11) : 137A - 137A
  • [40] Der(9) deletions and response to STI571(Glivec®) treatment in chronic phase CML patients.
    Cuthbert, GD
    Freeman-Edward, JC
    Lennard, AL
    Chase, A
    Capdeville, R
    Goldman, JM
    O'Brien, SG
    Bown, NP
    BLOOD, 2001, 98 (11) : 256B - 256B
12345